Lexeo Therapeutics, Inc. Common Stock (LXEO) vs OraSure Technologies, Inc. (OSUR)
A side-by-side comparison of Lexeo Therapeutics, Inc. Common Stock and OraSure Technologies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OSUR
OraSure Technologies, Inc.
$3.77HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — LXEO vs OSUR
growth of $100 · dividends reinvested · last 3yLXEO -66.1% (-30.3%/yr)OSUR -24.2% (-8.8%/yr)OSUR compounded faster over this window
LXEO OSUR
LXEO vs OSUR: by the numbers
- •OSUR is the larger company ($260M vs $259M market cap).
- •Both run net losses; LXEO's is the smaller (0.00% vs -43.70% net margin).
Metrics side by side
Valuation
| Metric | LXEO | OSUR |
|---|---|---|
| P/S ratio | N/A | 2.31 |
| P/B ratio | 1.10 | 0.82 |
Profitability
| Metric | LXEO | OSUR |
|---|---|---|
| Gross margin | 0.00% | 41.38% |
| Operating margin | 0.00% | -59.23% |
| Net margin | 0.00% | -43.70% |
| ROE | -37.12% | -15.46% |
| ROIC | -39.76% | -15.00% |
Growth (annualized)
| Metric | LXEO | OSUR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -13.12% |
| Total return CAGR (5Y) | N/A | -17.56% |
Go deeper
Dig into the metrics
Lexeo Therapeutics, Inc. Common Stock ROEOraSure Technologies ROELexeo Therapeutics, Inc. Common Stock operating marginOraSure Technologies operating marginLexeo Therapeutics, Inc. Common Stock revenue growthOraSure Technologies revenue growthLexeo Therapeutics, Inc. Common Stock free cash flowOraSure Technologies free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.